Endocrine Abstracts

Objective: Several studies reported that a long-time therapy with somatostatin analogs (SSTa) in acromegaly could induce persistent remission event after drug withdrawal. The aim of this study was to evaluate GH/IGF-I secretion after SSTa discontinuation in a series of acromegalic patients.Materials and methods: Data of 21 patients regularly referred to our Centre and previously included in a multicentre study, have been updated at the last available fol...

Background: In acromegalic patients, quality of life reduction and neuropsychological impairment are common, in addition to well-known complications related to the pituitary adenoma and to the GH/IGF-I excess. Acromegalic patients need a lot of outpatient visits and a multidisciplinary approach during the management of the disease and its comorbidities. Aim of the project is to analyze the role of an electronic health device (eHD) with remote monitoring in management of acrome...

Aneurysmal bone cysts (ABCs) are rare pseudotumoral bone lesions with potential aggressive behavior due to the extensive destruction of surrounding bone. Besides surgery, denosumab has been investigated as a treatment for benign fibro-osseous lesions. As for ABCs, pediatric experience is limited, reporting mainly beneficial effects on lesions growth and associated pain. Some reports included well known side effects associated with denosumab, such as the rebound hypercalcemia a...

Context: Available data on the natural history of pituitary incidentalomas (PI) are not strong enough to draw any evidence-based conclusion on timing and length of follow up of these masses, due to heterogeneity and low sample sizes.Objective: To describe the characteristics and the natural history of PI using data from a large cohort of patients investigated in two Italian Pituitary Centers.Patients and methods: Retrospective stud...

Background: primary empty sella (ES) represents a frequent finding (up to 35% of the general population). According to the literature, the prevalence of hypopituitarism in ES ranges between 19-52%. Data on the natural history of ES over a long time, especially in incidental ES, are still lacking and the management can be challenging.Objective: our primary aim was to assess in a large cohort of patients with ES the prevalence and determinants of hypopitui...